ENSC — Ensysce Biosciences Balance Sheet
0.000.00%
Last trade - 00:00- $4.31m
- -$0.02m
- $5.07m
Annual balance sheet for Ensysce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 12.3 | 3.15 | 1.12 | 3.5 | 4.31 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.442 | 0.277 | 0.098 | 0.124 | 0.42 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 15.7 | 5.3 | 2.29 | 5.34 | 7.24 |
| Net Property, Plant And Equipment | 0 | 0 | 0 | — | 0.124 |
| Other Long Term Assets | |||||
| Total Assets | 16.4 | 5.89 | 2.71 | 5.6 | 7.45 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 16.5 | 9.46 | 3.33 | 2.21 | 4.57 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 24.3 | 9.6 | 3.03 | 1.89 | 4.24 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -7.88 | -3.71 | -0.323 | 3.71 | 3.21 |
| Total Liabilities & Shareholders' Equity | 16.4 | 5.89 | 2.71 | 5.6 | 7.45 |
| Total Common Shares Outstanding |